Scott Adams, the sharp-witted creator of the Dilbert comic strip, turned to President Donald Trump for urgent assistance in his fight against advanced prostate cancer. Facing delays from his healthcare provider that could prove fatal, Adams took to X with a direct plea. “On Monday, I will ask President Trump, via X, to help save my life. He offered to help me if I needed it. I need it,” he posted.
Adams detailed his dire situation, explaining that the cancer had metastasized and his provider, Kaiser of Northern California, had greenlit the use of Pluvicto, a targeted radiation therapy recently expanded by the FDA for earlier treatment stages. Yet, the simple IV procedure remained unscheduled despite repeated efforts.
“As many of you know, I have metastasized prostate cancer. My healthcare provider, Kaiser of Northern California, has approved my application to receive a newly FDA-approved drug called Pluvicto. But they have dropped the ball in scheduling the brief IV to administer it and I can’t seem to fix that. I am declining fast,” Adams wrote.
He emphasized that while Pluvicto offers no cure, it has extended life for many in similar circumstances. “It is not a cure, but it does give good results to many people.”
Trump wasted no time responding. On Truth Social, he shared a screenshot of Adams’ message and added a succinct “on it!”
Health and Human Services Secretary Robert F. Kennedy Jr. quickly followed up on X: “Scott. How do I reach you? The President wants to help.”
The intervention paid off. Adams soon announced he had locked in an appointment for the treatment the next day, crediting the high-level push for cutting through the red tape. This episode exposes the frustrations baked into a healthcare system bogged down by bureaucracy, where even approved lifesaving options can slip through the cracks—raising questions about whether such hurdles stem from inefficiency or deeper systemic issues in how Big Pharma and insurers operate.
Similar stories have surfaced before, with patients battling delays for innovative therapies amid regulatory tangles. As STAT News reported, Pluvicto’s recent FDA nod for broader use aimed to address such gaps, but real-world access remains uneven. For Adams, Trump’s hands-on approach delivered results when standard channels failed, proving once again that decisive leadership can make all the difference in personal crises.
